With a U.S. judge refusing to grant an injunction against generic versions of it’s top-selling drug Seroquel last Friday, the Wall Street Journal reports that AstraZeneca is struggling to control costs and find acquisitions that will help it to exploit new product lines. The decision follows the U.K. High Court’s decision last week that AstraZeneca’s patent on Seroquel is invalid in Britain.
Article →
